294 related articles for article (PubMed ID: 25139843)
21. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
22. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
Peterson LR
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
[TBL] [Abstract][Full Text] [Related]
23. Transmission in the community of clonal Proteus mirabilis carrying VIM-1 metallo-beta-lactamase.
Tsakris A; Ikonomidis A; Poulou A; Spanakis N; Pournaras S; Markou F
J Antimicrob Chemother; 2007 Jul; 60(1):136-9. PubMed ID: 17491004
[TBL] [Abstract][Full Text] [Related]
24. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
Réa-Neto A; Niederman M; Lobo SM; Schroeder E; Lee M; Kaniga K; Ketter N; Prokocimer P; Friedland I
Curr Med Res Opin; 2008 Jul; 24(7):2113-26. PubMed ID: 18549664
[TBL] [Abstract][Full Text] [Related]
27. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.
Pillay T; Pillay DG; Adhikari M; Sturm AW
Am J Perinatol; 1998 Jan; 15(1):47-51. PubMed ID: 9475688
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model.
Islam K; Sime FB; Wallis SC; Bauer MJ; Naicker S; Won H; Zowawi HM; Choudhury MA; Shirin T; Habib ZH; Harris PNA; Flora MS; Roberts JA
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0016222. PubMed ID: 35924928
[TBL] [Abstract][Full Text] [Related]
29. OXA-48-like carbapenemases in
Sattler J; Noster J; Stelzer Y; Spille M; Schäfer S; Xanthopoulou K; Sommer J; Jantsch J; Peter S; Göttig S; Gatermann SG; Hamprecht A
Emerg Microbes Infect; 2024 Dec; 13(1):2353310. PubMed ID: 38712879
[TBL] [Abstract][Full Text] [Related]
30. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
[TBL] [Abstract][Full Text] [Related]
31. Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam.
Mokaddas EM; Sanyal SC
J Chemother; 1999 Apr; 11(2):93-6. PubMed ID: 10326738
[TBL] [Abstract][Full Text] [Related]
32. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.
Gavin PJ; Suseno MT; Thomson RB; Gaydos JM; Pierson CL; Halstead DC; Aslanzadeh J; Brecher S; Rotstein C; Brossette SE; Peterson LR
Antimicrob Agents Chemother; 2006 Jun; 50(6):2244-7. PubMed ID: 16723596
[TBL] [Abstract][Full Text] [Related]
33. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
Chang SC; Hsu LY; Luh KT; Hsieh WC
J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175
[TBL] [Abstract][Full Text] [Related]
34. The first detection of CTX-M-14 extended-spectrum beta-lactamase among diverse beta-lactamase-producing Proteus mirabilis clinical isolates.
Yong D; Lim YS; Roh KH; Choi YS; Park DY; Yum JH; Kim JM; Lee K; Chong Y
Diagn Microbiol Infect Dis; 2006 Mar; 54(3):237-9. PubMed ID: 16427241
[TBL] [Abstract][Full Text] [Related]
35. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Thomson KS; Moland ES
Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report.
Berg ML; Crank CW; Philbrick AH; Hayden MK
Ann Pharmacother; 2008 Feb; 42(2):207-12. PubMed ID: 18230703
[TBL] [Abstract][Full Text] [Related]
37. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
38. Comparative effectiveness of cefmetazole versus carbapenems and piperacillin/tazobactam as initial therapy for bacteremic acute cholangitis: A retrospective study.
Aoto K; Inose R; Kosaka T; Shikata K; Muraki Y
J Infect Chemother; 2024 Mar; 30(3):213-218. PubMed ID: 37832824
[TBL] [Abstract][Full Text] [Related]
39. [In vitro activity of piperacillin-tazobactam against Klebsiella pneumoniae clinical isolates, producers or not of extended spectrum beta-lactamases].
Alarcón T; de la Obra P; López-Hernandez S; de las Cuevas C; López-Brea M
Rev Esp Quimioter; 1999 Sep; 12(3):229-33. PubMed ID: 10878513
[TBL] [Abstract][Full Text] [Related]
40. [Extended-spectrum-beta-lactamase-producing Proteus mirabilis: laboratory-based surveillance in cooperation with 12 clinical laboratories in the Kinki Region of Japan].
Nakamura T; Komatsu M; Shimakawa K; Sueyoshi N; Satoh K; Toyokawa M; Nishio H; Wada Y; Orita T; Kofuku T; Sakamoto M; Okamoto K; Akagi M; Kinoshita S
Kansenshogaku Zasshi; 2006 May; 80(3):231-7. PubMed ID: 16780129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
